Financials in USD. Standardized financial statements.
A compact view of how MGC Pharmaceuticals Limited turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $3.39M | $4.73M | $3.00M | $2.08M | $656,237 | $296,811 | $120,242 | $2,197 | $0 | $11,357 |
| Revenue Growth? | -28.4% | +57.9% | +44.1% | +216.8% | +121.1% | +146.8% | +5373.0% | 0.0% | -100.0% | 0.0% |
| Cost of Revenue? | $2.69M | $3.17M | $2.26M | $1.91M | $356,642 | $119,340 | $158,073 | $15,011 | $0 | $0 |
| Gross Profit? | $1.29M | $1.56M | $736,492 | -$306,000 | $299,595 | $177,471 | -$37,831 | -$12,814 | $0 | $11,357 |
| Gross Margin? | +38.0% | +33.0% | +24.6% | -14.7% | +45.7% | +59.8% | -31.5% | -583.2% | 0.0% | +100.0% |
| Operating Expenses? | $17.05M | $14.47M | $13.38M | $11.98M | $9.34M | $9.26M | $8.57M | $6.14M | $3.80M | $5.35M |
| Operating Income? | -$15.49M | -$15.50M | -$11.94M | -$11.80M | -$8.71M | -$7.05M | -$7.29M | -$4.22M | -$3.63M | -$5.34M |
| EBITDA? | -$20.38M | -$15.16M | -$17.05M | -$18.66M | $880,816 | -$8.54M | -$8.40M | -$6.09M | -$3.80M | -$5.35M |
| Income Before Tax | -$21.13M | -$20.77M | -$15.90M | -$18.77M | -$11.03M | -$8.99M | -$8.50M | -$6.23M | -$3.80M | -$5.34M |
| Income Tax Expense | $2,017 | -$420,000 | -$535,000 | -$429,000 | $27,315 | -$1.90M | -$358,000 | -$72,919 | $0 | $0 |
| Net Income? | -$20.82M | -$20.35M | -$15.87M | -$19.36M | -$11.01M | -$8.25M | -$8.14M | -$6.16M | -$3.80M | -$5.34M |
| EPS? | $-7.10 | $-7.90 | $-8.30 | $-14.00 | $-9.11 | $-7.33 | $-8.43 | $-10.20 | $-13.43 | $-33.37 |
| Diluted EPS? | $-7.07 | $-7.90 | $-8.30 | $-14.00 | $-9.11 | $-7.33 | $-8.43 | $-10.20 | $-13.43 | $-33.37 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality